GlassScriptPhysician profile
Hiba Ali
NPI 1811426653
$622.52
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $60.65 · 2023: $13.23 · 2024: $188 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.76 | 2024-2025 | Evenity, Prolia, Prolia |
| Corcept Therapeutics | $92.94 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $84.83 | 2024 | Voquezna |
| Vivus LLC | $69.55 | 2021-2022 | |
| Spr Therapeutics, INC | $44.73 | 2025 | Sprint Pns System |
| Surmodics, INC. | $41.67 | 2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Pounce Venous Thrombectomy System |
| Bridgebio Pharma, INC. | $34.51 | 2025 | Attruby |
| Vertex Pharmaceuticals Incorporated | $25.25 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.60 | 2021 | |
| Genzyme Corporation | $21.78 | 2024 | |
| Novo Nordisk INC | $19.52 | 2022 | |
| Lilly USA, LLC | $17.39 | 2021 | |
| Ibsa Pharma INC. | $13.23 | 2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiba Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.